INTEGRIS-PSC study evaluates bexotegrast vs PBO at doses 40/80/160/320mg in patients (n=121) with PSC for 12wks. The 320mg group enrolled 27 vs 9 patients & with final data expected by mid-2024
The 1EP includes safety & tolerability whereas 2EP includes tolerability. The results depicted bexotegrast to be well tolerated with no DRAEs as 96% of patients in the 320mg group completed the 12wks. treatment with no drug-related severe or SAEs
The exploratory endpoints assessing the change in liver fibrosis markers (ELF & PRO-C3), liver biochemistry & MRI Imaging, showed a reduced ELF & PRO-C3 score vs PBO at 12wks. & an increase in relative enhancement on contrast MRI vs a decrease in PBO
Ref: Pliant Therapeutics | Image: Pliant Therapeutics
Related News:- Pliant Therapeutics Reports an Initiation of P-IIb Trial (BEACON-IPF) for Bexotegrast to Treat Idiopathic Pulmonary Fibrosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
